C4 Therapeutics (CCCC) Non-Current Deffered Revenue (2019 - 2025)
Historic Non-Current Deffered Revenue for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $19.9 million.
- C4 Therapeutics' Non-Current Deffered Revenue fell 3057.81% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 3057.81%. This contributed to the annual value of $28.5 million for FY2024, which is 3045.29% up from last year.
- C4 Therapeutics' Non-Current Deffered Revenue amounted to $19.9 million in Q3 2025, which was down 3057.81% from $21.2 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Non-Current Deffered Revenue high stood at $50.9 million for Q1 2021, and its period low was $15.8 million during Q1 2023.
- Its 5-year average for Non-Current Deffered Revenue is $24.9 million, with a median of $21.2 million in 2025.
- Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first crashed by 6262.23% in 2022, then soared by 4599.19% in 2024.
- C4 Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $24.4 million in 2021, then plummeted by 30.67% to $16.9 million in 2022, then rose by 29.12% to $21.8 million in 2023, then soared by 30.45% to $28.5 million in 2024, then tumbled by 30.11% to $19.9 million in 2025.
- Its Non-Current Deffered Revenue was $19.9 million in Q3 2025, compared to $21.2 million in Q2 2025 and $25.1 million in Q1 2025.